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THE present study was performed to: (a) evaluate the
effects of kinin B1 (Sar{D-Phe8}-des-Arg9-BK; 10nmol/
kg)  and  B2 (bradykinin  (BK);  10nmol/kg)  receptor
agonists  on  plasma  extravasation  in  selected  rat
tissues; (b) determine the contribution of a lipopoly-
saccharide (LPS) (100 m g/kg) to the effects triggered
by  B1 and  B2 agonists;  and  (c)  characterize  the
selectivity  of  B1 ({Leu8}desArg9-BK; 10nmol/kg)  and
B2 (HOE 140; 10nmol/kg) antagonists as inhibitors of
this kinin-induced phenomenon. B1 and B2 agonists
were shown to increase plasma extravasation in the
duodenum, ileum and also in the urinary bladder of
the  rat.  LPS  pretreatment  enhanced  the  plasma
extravasation mediated only by the B1 agonist in the
duodenum, ileum, trachea, main and segmentar bron-
chi. These effects were prevented by the B1. but not
the B2 antagonist. In normal rats, the B2 antagonist
inhibited  the  effect  of  B2 agonist  in  all  the  tissues
analyzed. However, in LPS-treated rats, the B2 antago-
nist was ineffective in the urinary bladder.
These  results  indicate  that  kinins  induce  plasma
extravasation  in  selected  rat  tissues  through activa-
tion of B1 and B2 receptors, and that LPS selectively
enhances the kinin effect on the B1 receptor in the
duodenum, ileum, trachea and main and segmentar
bronchi, and may increase B1 receptor expression in
these tissues.
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Introduction
Kinins are powerful pro-inflammatory peptides that
are released from their precursors, the kininogens, by
proteolytic  cleavage  of  specific  and  non-specific
kininogenases.1 Pharmacological actions of kinins are
mediated by B1 and B2 receptors, the distribution of
which has been studied through the use of specific
and  selective  antagonists,2–4 and  the  analysis  of
protein expression levels.5
The kinin  B2 receptor is constitutively expressed
in several different cell types and tissues, and most
of the actions of kinins are mediated by this recep-
tor.6–8 In contrast, B1 receptors are rarely expressed
constitutively but, rather, their expression is induced
by  experimental  interventions such  as  exposure  of
tissue  in  vivo or  in  vitro to  bacterial  lipopoly-
saccharides  (LPS),  interleukin-1b or  to  ultraviolet
irradiation.6
Previously, we exploited the effect of LPS on kinin
B1 receptors  to  demonstrate  the  role  of  these
receptors in mediating the vasodilatation in vascular
beds of pretreated rats.4 These results were observed
only when we used the B1 agonist, Sar[D-Phe8]-des-
Arg9-BK, which is resistant to metabolism by angio-
tensin-converting enzyme, neutral endopeptidase and
aminopeptidases.9
In the present study, we investigated the kinin B1
receptor-mediated plasma  extravasation in  two  sec-
tions of the gastrointestinal tract, in the airways and
the urinary bladder, in normal and LPS-treated rats.
Materials and methods
Evans blue, HOE 140 (icatibant) and formamide were
obtained from Sigma (St. Louis, MO, USA). Bradykinin
(BK), Sar[D-Phe8]-des-Arg9-BK, and [Leu8]desArg9-BK
were gifts from D. Regoli (Department of Pharmacol-
ogy at the Universit´ e de Sherbrooke, Canada).  The LPS
used in this study was from Escherichia coli (serotype
0127:B8) from Difco (Detroit, MI, USA).
Conscious male Wistar rats (200–300g) were used
in  these  experiments.  Protein  extravasation  was
evaluated by measuring tissue content of Evans blue
dye, as previously described.10 In brief, EB (20mg/kg
of a solution containing 25mg/ml in 0.9% NaCl) was
injected alone or concomitantly with either kinin B2
receptor  agonist  (BK;  10nmol/kg)  or  the  kinin  B1
receptor  agonist  (Sar[D-Phe8]-des-Arg9-BK;  10nmol/
kg),  in control animals and animals pretreated 24h
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administered  through  the  caudal  vein.  In  other
experiments,  normal  and  LPS-treated  animals  were
injected with a selective kinin B2 receptor antagonist
(HOE  140;  10nmol/kg),  or  a  selective  kinin  B1
receptor antagonist ([Leu8]desArg9-BK; 10nmol/kg),
5min before the application of B1 or B2 agonists.
Evans blue was administered and, after 10min, the
animals  were  decapitated  and  exsanguinated.  The
thorax was  cut  open  and  the lungs  were  perfused
with 20ml  of  0.9%  NaCl (10ml/min) via a cannula
inserted into the pulmonary artery through the right
ventricle, to remove the intravascular pulmonary dye.
The  trachea,  main  and  segmentar  bronchi,  duode-
num, ileum and urinary bladder were dissected and
weighed.  One-half  of  each  organ  was  put  in  for-
mamide while the other half was dried at 50°C for
24h. The  concentration  of  Evans  blue  dye  in  the
tissues was determined at 620nm, using an enzyme-
linked  immunosorbent  assay  plate  reader,  and  was
expressed  in  micrograms  per  gram  of  dry  weight
tissue to avoid error due to edema.10
Results  are  expressed  as  means  (SEM,  and  data
obtained in various groups of animals were compared
by  analysis  of  variance  followed  by  a  post-hoc
Neuman–Keuls’ test, when necessary. p < 0.05 was
considered significant.
Results
In  the  first  series  of  experiments,  we  studied  the
effects of a kinin B2 receptor agonist (bradykinin) on
plasma extravasation in control and LPS-treated rats
(Fig. 1). Bradykinin (10nmol/kg) increased the plasma
extravasation in the duodenum, ileum, urinary bladder,
trachea, and main and segmentar bronchi by 43, 30,
78, 58, 27, and 29%, respectively. The injection of the
B2 receptor antagonist HOE 140 (10nmol/kg), before
BK, reduced the plasma extravasation to control values
in all tissues analyzed in this work. Pretreatment with a
LPS (100 m g/kg), for 24h, resulted in increased plasma
extravasation only in the urinary bladder, by 59%. In
LPS-treated rats, the injection of B2 agonist produced
results similar to those observed with BK in control
animals.  Thus,  LPS  did  not  exert  any  significant
influence  on  plasma  extravasation  induced  by  B2
agonist. Previous injection with the B2 antagonist in
LPS-treated  rats  significantly  reduced  the  plasma
extravasation induced by BK in the duodenum (31%),
ileum  (22%),  trachea  (32%),  and  main  (33%)  and
segmentar  bronchi  (29%),  but  not  in  the  urinary
bladder. As expected, the B1 antagonist ([Leu8]desArg9-
BK; 10nmol/kg) had no effect on plasma extravasation
induced by BK in LPS-treated rats.
In the second series of experiments, we studied the
effects of a selective B1 agonist (Sar[D-Phe8]-des-Arg9-
BK; 10nmol/kg) on plasma extravasation in control
and LPS-treated rats (Fig. 2). This B1 agonist increased
the  plasma  extravasation  in  the  duodenum  (33%),
ileum  (35%),  and trachea (38%). The injection of  a
selective B1 antagonist ([Leu8]desArg9-BK), before the
administration  of  B1 agonist,  did  not  prevent  the
plasma  extravasation  in  the  duodenum,  ileum  and
trachea induced  by  B1 agonist, suggesting  a  partial
agonist activity on the B2 receptor. The injection of B1
agonist in LPS-treated rats increased plasma extravasa-
tion in the urinary bladder (54%), and main (29%) and
segmentar  (48%)  bronchi.  An  increase  in  plasma
extravasation  was  also  observed  in  the  duodenum
(56%), ileum (38%) and trachea (37%), similar to that
observed in response to B1 agonist, in non-LPS treated
rats. In LPS-pretreated rats, the B1 antagonist injected
before the B1 agonist significantly reduced the plasma
extravasation in all tissues studied, with the exception
of  the  urinary  bladder. The  B2 antagonist  did  not
prevent the plasma extravasation mediated by the B1
agonist in LPS-pretreated rats.
Discussion
The results presented indicate that kinins are able to
induce plasma extravasation in all the tissues of rats
analyzed in this study, namely the duodenum, ileum,
urinary  bladder,  trachea,  and  main  bronchi  and
segmentar bronchi. The effects appear to be mediated
by  B1 and/or  B2 receptors.  B1 receptor-mediated
plasma extravasation responses were enhanced after
LPS treatment in the duodenum, ileum, trachea, main
and  segmentar  bronchi,  in  which  the  B1 agonist
(Sar[D-Phe8]-des-Arg9-BK)  induced  a  significant
increase in the dye content, suggesting that this toxin
promotes the formation of B1 receptor in the rat, as it
does in the rabbit and other animal species.11,12
It is generally accepted that, while the expression
of  B2 receptors  is  constitutive,  expression  of  B1
receptors is induced by tissue injury/inflammation.11
In this study, the presence and the de novo expres-
sion  of  B1 receptors  following  LPS  treatment  was
found in main and segmentar bronchi, the duodenum
and the ileum, and was demonstrated by the fact that
the  specific  and  selective  B1 antagonist  ([Leu8]de-
sArg9-BK) completely prevented the combined effect
of LPS and B1 agonist. In addition, the B2 antagonist
was found to be inactive against B1 agonist. In the
urinary  bladder,  LPS  alone  induced  a  significant
increase in plasma extravasation, but did not promote
de novo expression of B1 receptors because the B1
antagonist  had  no  effect  against  LPS  treatment.
Recently,  studies  have  provided  evidence  for  the
expression of  kinin  B1 receptors mediating bladder
smooth muscle contraction after cyclophosphamide-
induced  inflammation  in  rats.8 Also,  other  authors
showed evidence for the time-dependent induction of
B1 receptor expression in mice mediating the contrac-
tion of urinary bladder.13 However, our results suggest
that the LPS-induced increase in plasma extravasation
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nisms  that  may  be  independent  of  kinin  receptor
activation.  This  finding  requires  further
investigation.
The  B1 receptor  is  known  to  be  constitutively
expressed in vivo both in the dog coronary system
and in the cat pulmonary vascular bed.11 In this study,
we used the same B1 agonist (Sar[D-Phe8]-des-Arg9-
BK) as that used previously8 because this drug is more
resistant to enzymatic metabolism than the alternative
B1 agonist desArg-BK.6,9 Our results showed that B1
receptor-mediated plasma extravasation occurred in
the  duodenum,  ileum  and  trachea  of  normal  rats.
Moreover, the effect of this drug was not inhibited by
B1 receptors mediate plasma extravasation in LPS-treated rats
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FIG.  1.  Effects  of  kinin  B2 agonist,  B2 antagonist  and  lipopolysaccharide  (LPS),  alone  and  in  combination,  on  plasma
extravasation in various organs of the rat. Duo, Duodenum; Ile, ileum; Bla, urinary bladder; Segm bronchi, segmentar bronchi.
Columns indicate the means, and vertical bars the standard error of six rats. LPS, LPS-treated rats; B2 AG, B2 agonist; B2 ANT,
B2 antagonist; B1 ANT, B1 antagonist. * p < 0.05, ** p < 0.01, significance with respect to controls, and ©p < 0.05, ©©p < 0.01
significance as compared with B2 agonist and LPS + B2 agonist.treatment with the B1 antagonist, suggesting a partial
agonist activity of the B1 agonist at the B2 receptor.
On  the  contrary,  the  treatment  with  LPS,  which
significantly increased the effect of the B1 agonist in
the duodenum, ileum, trachea, main and segmentar
bronchi, was blocked by the B1 antagonist but not by
the B2 antagonist. Increased plasma extravasation has
been  attributed  to  B2 receptors.6 Our  results  are
consistent with other vascular responses mediated by
B1 receptors observed in LPS-pretreated rabbits14 and
rats.4,5,15
Bradykinin  increased  plasma  extravasation  in  all
tissues analyzed in this report. This effect appears to
be  due  to activation of  B2 receptors as it was  not
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FIG.  2.  Effects  of  kinin  B1 agonist,  B1 antagonists  and  lipopolysaccharide (LPS),  alone  and  in  combination,  on  plasma
extravasation in various organs of the rat. Duo, Duodenum; Ile, ileum; Bla, urinary bladder; Segm bronchi, segmentar bronchi.
Columns indicate the means, and vertical bars the standard error of six rats. LPS, LPS-treated rats; B1 AG, B1 agonist; B1 ANT,
B1 antagonist; B2 ANT, B2 antagonist. * p < 0.05, ** p < 0.01, significance with respect to controls, ©p < 0.05, ©©p < 0.01
significance as compared with B1 agonist and LPS + B1 agonist.enhanced by the pretreatment of the animal with LPS
and this effect was blocked by the B2 antagonist. This
conclusion is further supported by the finding that
the  B1 antagonist was  found  to  be  inactive  against
bradykinin-induced plasma extravasation.
It is therefore concluded that bradykinin and the
enzyme-resistant B1 agonist (Sar[D-Phe8]-des-Arg9-BK)
promote  plasma  extravasation  by  acting  on  two
receptor types, B1 and B2. Furthermore, we showed
that B2 receptors are present in rat duodenum, ileum,
urinary  bladder,  trachea  and  main  and  segmentar
bronchi, mediating plasma extravasation. Most impor-
tantly, we demonstrated that LPS is able to promote
the de novo formation of kinin B1 receptors, which
subsequently  mediate plasma extravasation in these
tissues.
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